VEGFA and cancer: Targeting VEGF by many agents, including anti-VEGF monoclonal antibodies, have been developed showing promising effect in vitro, but their effects in vivo settings or in cancer patients are limited due several adverse effects, such as hypertension, gastrointestinal-perforation, bleeding, impairment of wound healing etc. (18).